BCA
MRTX

Berman Capital Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Berman Capital Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$34K Buy
196
+90
+85% +$14.5K 0.01% 827
2021
Q2 		$17K Buy
106
+34
+47% +$5.46K ﹤0.01% 979
2021
Q1 		$12K Buy
+72
New +$14.3K ﹤0.01% 986

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Berman Capital Advisors's MRTX Position: Q3 2021 in Review

Berman Capital Advisors increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 85% in Q3 2021, buying an estimated $14.5K and bringing the position to 196 shares worth $34K. The position accounts for 0.01% of the portfolio, ranked #827.

Berman Capital Advisors first reported a position in MRTX in Q1 2021 and has held it in 3 quarters since. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

  • Berman Capital Advisors held 196 shares of Mirati Therapeutics, Inc. Common Stock worth $34K as of Q3 2021.
  • Berman Capital Advisors bought 90 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $14.5K.
  • Mirati Therapeutics, Inc. Common Stock made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #827 holding.
  • Berman Capital Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 3 quarters since.
  • 238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.